Cotrimoxazole Prophylaxis Discontinuation among Antiretroviral-Treated HIV-1-Infected Adults in Kenya: A Randomized Non-inferiority Trial

PLoS Medicine

Volumn 13, Issue 1, 2016, Pages

  Polyak, Christina S ^a,b   Yuhas, Krista ^b   Singa, Benson ^c   Khaemba, Monica ^c   Walson, Judd ^b   Richardson, Barbra A ^b   John Stewart, Grace ^b  

^a WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c KENYA MEDICAL RESEARCH INSTITUTE   (Kenya)

Author keywords

[No Author keywords available]

Indexed keywords

COTRIMOXAZOLE; ANTIMALARIAL AGENT; ANTIRETROVIRUS AGENT; DRUG COMBINATION; SULFADOXINE; TRIMETHOPRIM; TRIMETHOPRIM, SULFADOXINE DRUG COMBINATION;

ADULT; ANTIBIOTIC RESISTANCE; ARTICLE; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; IMMUNE RECONSTITUTION INFLAMMATORY SYNDROME; IMMUNE RESPONSE; KENYA; MAJOR CLINICAL STUDY; MALE; MORBIDITY; MORTALITY; PREVALENCE; SEROPREVALENCE; CONTROLLED STUDY; DRUG COMBINATION; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; MALARIA; MIDDLE AGED; POST EXPOSURE PROPHYLAXIS; PROCEDURES; RANDOMIZED CONTROLLED TRIAL;

ADULT; ANTI-RETROVIRAL AGENTS; ANTIMALARIALS; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HIV-1; HUMANS; KENYA; MALARIA; MALE; MIDDLE AGED; POST-EXPOSURE PROPHYLAXIS; SULFADOXINE; TRIMETHOPRIM;

EID: 84961288576     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001934     Document Type: Article

References (30)

1. Anglaret X, Chêne G, Attia A, Toure S, Lafont S, et al. (1999) Early chemoprophylaxis with trimethoprim-sulphamethoxazole for HIV-1-infected adults in Abidjan, Côte d’Ivoire: a randomised trial. Lancet 353: 1463–1468. 10232311
2. Wiktor SZ, Sassan-Morokro M, Grant AD, Abouya L, Karon JM, et al. (1999) Efficacy of trimethoprim-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Côte d’Ivoire: a randomised controlled trial. Lancet 353: 1469–1475. 10232312
3. Mermin J, Ekwaru JP, Liechty CA, Were W, Downing R, et al. (2006) Effect of co-trimoxazole prophylaxis, antiretroviral therapy, and insecticide-treated bednets on the frequency of malaria in HIV-1-infected adults in Uganda: a prospective cohort study. Lancet 367: 1256–1261. 16631881
4. Hamel MJ, Greene C, Chiller T, Ouma P, Polyak C, et al. (2008) Does cotrimoxazole prophylaxis for the prevention of HIV-associated opportunistic infections select for resistant pathogens in Kenyan adults? Am J Trop Med Hyg 79: 320–330. 18784222
5. Badri M, Ehrlich R, Wood R, Maartens G, (2001) Initiating co-trimoxazole prophylaxis in HIV-infected patients in Africa: an evaluation of the provisional WHO/UNAIDS recommendations. AIDS 15: 1143–1148. 11416716
6. Suthar AB, Granich R, Mermin J, Van Rie A, (2012) Effect of cotrimoxazole on mortality in HIV-infected adults on antiretroviral therapy: a systematic review and meta-analysis. Bull World Health Organ 90: 128C–138C. doi: 10.2471/BLT.11.093260 22423164
7. Chintu C, Bhat GJ, Walker AS, Mulenga V, Sinyinza F, et al. (2004) Co-trimoxazole as prophylaxis against opportunistic infections in HIV-infected Zambian children (CHAP): a double-blind randomized placebo-controlled trial. Lancet 364: 1865–1871. 15555666
8. Lowrance D, Makombe S, Harries A, Yu J, Aberle-Grasse J, et al. (2007) Lower early mortality rates among patients receiving antiretroviral treatment at clinics offering cotrimoxazole prophylaxis in Malawi. J Acquir Immune Defic Syndr 46: 56–61. 17972365
9. Bwakura-Dangarembizi M, Kendall L, Bakeera-Kitaka S, Nahirya-Ntege P, Keishanyu R, et al. (2014) A randomized trial of prolonged co-trimoxazole in HIV-infected children in Africa. N Engl J Med 370: 41–53. doi: 10.1056/NEJMoa1214901 24382064
10. Campbell JD, Moore D, Degerman R, Kaharuza F, Were W, et al. (2012) HIV-infected Ugandan adults taking antiretroviral therapy with CD4 counts >200 cells/L who discontinue cotrimoxazole prophylaxis have increased risk of malaria and diarrhea. Clin Infect Dis 54: 1204–1211. doi: 10.1093/cid/cis013 22423133
11. Walker AS, Ford D, Gilks CF, Munderi P, Ssali F, et al. (2010) Daily co-trimoxazole prophylaxis in severely immunosuppressed HIV-infected adults in Africa started on combination antiretroviral therapy: an observational analysis of the DART cohort. Lancet 375: 1278–1286. doi: 10.1016/S0140-6736(10)60057-8 20347483
12. McNaghten AD, Hanson DL, Jones JL, Dworkin MS, Ward JW, (1999) Effects of antiretroviral therapy and opportunistic illness primary chemoprophylaxis on survival after AIDS diagnosis. AIDS 13: 1687–1695. 10509570
13. Kaplan JE, Benson C, Holmes KK, Brooks JT, Pau A, et al. (2009) Guidelines for prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. MMWR Recomm Rep 58: 1–207.
14. World Health Organization (2006) Guidelines on co-trimoxazole prophylaxis for HIV-related infections among children, adolescents and adults: recommendations for a public health approach. Geneva: World Health Organization.
15. Furrer H, Egger M, Opravil M, Bernasconi E, Hirschel B, et al. (1999) Discontinuation of primary prophylaxis against Pneumocystis carinii pneumonia in HIV-1-infected adults treated with combination antiretroviral therapy. N Engl J Med 340: 1301–1306. 10219064
16. Weverling GJ, Mocroft A, Ledergerber B, Kirk O, Gonzales-Lahoz J, et al. (1999) Discontinuation of Pneumocystis carinii pneumonia prophylaxis after start of highly active antiretroviral therapy in HIV-1 infection. Lancet 353: 1293–1298. 10218526
17. Mocroft A, Reiss P, Kirk O, Mussini C, Girardi E, et al. (2010) Is it safe to discontinue primary Pneumocystis jiroveci pneumonia prophylaxis in patients with virologically suppressed HIV infection and a CD4 cell count <200 cells/microL? Clin Infect Dis 51: 611–619. doi: 10.1086/655761 20645862
18. World Health Organization (2014) Guidelines on post-exposure prophylaxis for HIV and the use of co-trimoxazole prophylaxis for HIV-related infections among adults, adolescents and children: recommendations for a public health approach. December 2014 supplement to the 2013 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection. Geneva: World Health Organization.
19. National AIDS & STI Control Programme (2011) Guidelines for antiretroviral therapy in Kenya—4th edition. Nairobi: Ministry of Medical Services.
20. National AIDS & STI Control Programme (2011) National manual for the management of HIV-related opportunistic infections and conditions—1st edition. Nairobi: Ministry of Health.
21. National Institute of Allergy and Infectious Diseases (2004) Division of AIDS table for grading the severity of adult and pediatric adverse events. Bethesda (Maryland): National Institute of Allergy and Infectious Diseases.
22. Piaggio G, Elbourne DR, Pocock SJ, Evans SJ, Altman DG, (2012) Reporting of noninferiority and equivalence randomized trials: extension of the CONSORT 2010 statement. JAMA 308: 2594–2604. doi: 10.1001/jama.2012.87802 23268518
23. Walson JL, Brown ER, Otieno PA, Mbori-Ngacha DA, Wariua G, et al. (2007) Morbidity among HIV-1-infected mothers in Kenya: prevalence and correlates of illness during 2-year postpartum follow-up. J Acquir Immune Defic Syndr 46: 208–215. 17667334
24. Rubinstein LV, Gail MH, Santner TJ, (1981) Planning the duration of a comparative clinical trial with loss to follow-up and a period of continued observation. J Chronic Dis 34: 469–479. 7276137
25. StataCorp (2011) Stata 12. College Station (Texas): StataCorp.
26. Polyak CS, Yuhas K, Singa B, Khaemba M, Walson J, et al. (2014) CTX discontinuation among ART-treated adults: a randomized non-inferiority trial [abstact]. Conference on Retroviruses and Opportunistic Infections; 3–6 Mar 2014; Boston, MA, US.
27. Bloland PB, Redd S, Kazembe P, Tembenu R, Wirima J, et al. (1991) Co-trimoxazole for childhood febrile illness in malaria-endemic regions. Lancet 337: 518–520. 1671892
28. National AIDS & STI Control Programme (2012) HIV and AIDS profile: Homa Bay County. Nairobi: Ministry of Health
29. Pavlinac PB, Naulikha JM, Chaba L, Kimani N, Sangare LR, et al. (2014) Water filter provision and home-based filter reinforcement reduce diarrhea in Kenyan HIV-infected adults and their household members. Am J Trop Med Hyg 91: 273–280. doi: 10.4269/ajtmh.13-0552 24842881
30. Mermin J, Lule J, Ekwaru JP, Malamba S, Downing R, et al. (2004) Effect of co-trimoxazole prophylaxis on morbidity, mortality, CD4-cell count, and viral load in HIV infection in rural Uganda. Lancet 364: 1428–1434. 15488218